PRESS OFFICE
LISTING
Homenewsabout usContact UsWebsite
Welcome to the
Cipla Press Office
Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support.
Follow us:
 
News

Latest news

Access and affordability: South African launch of critical medications drives equitable accessIn putting healthcare in South Africa under the microscope, Covid-19 has exposed many weaknesses inherent in the country's fractured socio-economic environment. Yet, even before the pandemic reached our shores, equitable access to healthcare posed a significant obstacle for South Africa - a side effect of a tumultuous past. 2 Feb 2021 Read more

Cipla launches affordable tetanus vaccine to prevent tetanus deathsWhile the world remains focused on containing the spread of Covid-19, this should not avert our attention away from the ongoing battle to eradicate the many other diseases that can affect the quality of life for millions of South Africans. 8 Dec 2020 Read more

Landmark oncology drug registrationIn what is groundbreaking news for cancer sufferers diagnosed with blood cancers such as multiple myeloma (MM) or myelodysplastic syndromes, Cipla recently received regulatory approval for lenalidomide - a lifesaving immunomodulatory drug that activates and increases the number of immune system cells that identify and attack cancer cells - to bring this medication into the South African market at affordable prices. This will help to ensure that more cancer patients have access to this treatment, in line with Cipla's ethos of 'caring for life'. 7 Dec 2020 Read more

Alvotech and Cipla partner to ensure access to biosimilars in South AfricaBiopharmaceutical company Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets such as South Africa. The biosimilar portfolio will include five biosimilar medicines - two for oncology and three for treating auto-immune diseases. 5 Nov 2020 Read more

IDA awards top industry honour to Greater Tygerberg PartnershipIDA presents awards recognising innovative achievement in urban place management 12 Oct 2020 Read more


More news...

Contact Cipla

Email: az.oc.alpic@ofni
Tel: +27 21 943 4200
Customer Care: 080 222 6662
Website: www.cipla.co.za